Published
2025-06-25
Issue
Section
Review Article
License
Copyright (c) 2025 Marwa Sabbar Falih*, Neda Ibrahim Mahdi, Dhifaf A. Abdulabbas, Ruba Fahmi Abbas
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Author(s) warrant that permission to publish the article has not been previously assigned elsewhere.
Author(s) shall retain the copyright of their work and grant the Journal/Publisher right for the first publication with the work simultaneously licensed under:
OA - Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows for the copying, distribution and transmission of the work, provided the correct attribution of the original creator is stated. Adaptation and remixing are also permitted.
This license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types for non-commercial purposes.
How to Cite
Analytical chemical techniques for the determination of Meloxicam: A review
Marwa Sabbar Falih
Department of Chemistry, College of Science, Mustansiriyah University, Baghdad, 10045, Iraq
Neda Ibrahim Mahdi
Department of Medical Laboratory Technology, College of Health and Medical Technology, Almustafa University, Baghdad, 10045, Iraq
Dhifaf A. Abdulabbas
Department of Chemistry, College of Science, Mustansiriyah University, Baghdad, 10045, Iraq
Ruba Fahmi Abbas
Department of Chemistry, College of Science, Mustansiriyah University, Baghdad, 10045, Iraq
DOI: https://doi.org/10.59429/ace.v8i2.5683
Keywords: meloxicam (MLX), pharmaceuticals, biological samples, analytical methodologies
Abstract
This review discusses the analytical methods used to quantify meloxicam (MLX). It comprehensively surveys the accuracy of current techniques, including spectrophotometry, chromatography, electrochemistry, and other techiques, for meloxicam (MLX) determination. These well-established methods have been successfully applied to diverse sample types, such as pharmaceutical formulations and biological samples like plasma and muscle. A nonsteroidal anti-inflammatory medication (NSAID) called meloxicam MLX commonly prescribed for the management of pain and inflammation associated with various arthritic conditions, is available in multiple formulations, including injections, tablets, and gels. Classified as a derivative of oxicam and structurally related to piroxicam, meloxicam (MLX) belongs to the enolic acid class of compounds developed by Boehringer Ingelheim. Marketed under the trade name Mobic, its properties are similar to those of aspirin as an analgesic.
References
[1]. Ouarezki, R., & Guermouche, M. H. (2010). Liquid chromatographic determination of meloxicam in serum after solid phase extraction. Chemical Papers, 64(4), 429-433.
[2]. Jantharaprapap, R., & Stagni, G. (2007). Effects of penetration enhancers on in vitro permeability of meloxicam gels. International Journal of Pharmaceutics, 343(1-2), 26-33.
[3]. Shukla, M., Singh, G., Sindhura, B. G., Telang, A. G., Rao, G. S., & Malik, J. K. (2007). Comparative plasma pharmacokinetics of meloxicam in sheep and goats following intravenous administration. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 145(4), 528-532.
[4]. Brezovska, M., Jampilek, J., & Opatrilova, R. (2013). A review of HPLC methods used for determining the presence of meloxicam. Current Pharmaceutical Analysis, 9(1), 69-76.
[5]. Bharani, S. P., Naik, A. K., Parija, S. C., & Panda, S. K. (2020). Meloxicam induced toxicopathology studies in Wistar rats. Indian Journal of Animal Research, 54(3), 363-366.
[6]. de la Puente, R., Diez, R., Diez, M. J., Fernandez, N., Sahagun, A. M., Rodriguez, J. M., ... & Lopez, C. (2024). Pharmacokinetics of Meloxicam in Different Animal Species: A Comprehensive Review. Veterinary Sciences, 11(11), 519.
[7]. Grude, P., Guittard, J., Garcia, C., Daoulas, I., Thoulon, F., & Ebner, T. (2010). Excretion mass balance evaluation, metabolite profile analysis and metabolite identification in plasma and excreta after oral administration of [14C]‐meloxicam to the male cat: preliminary study. Journal of veterinary pharmacology and therapeutics, 33(4), 396-407.
[8]. Lehr, T., Narbe, R., Jöns, O., Kloft, C., & Staab, A. (2010). Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. Journal of veterinary pharmacology and therapeutics, 33(3), 277-286.
[9]. Han, H. K., & Choi, H. K. (2007). Improved absorption of meloxicam via salt formation with ethanolamines. European Journal of Pharmaceutics and Biopharmaceutics, 65(1), 99-103.
[10]. Al-Ameri, A. A. F., & Al-Gawhari, F. J. (2024). Formulation Development of Meloxicam Binary Ethosomal Hydrogel for Topical Delivery: In Vitro and In Vivo Assessment. Pharmaceutics, 16(7), 898.
[11]. Bekker, A., Kloepping, C., & Collingwood, S. (2018). Meloxicam in the management of post-operative pain: Narrative review. Journal of Anaesthesiology Clinical Pharmacology, 34(4), 450-457.
[12]. Schäufele, T. J., Kolbinger, A., Friedel, J., Gurke, R., Geisslinger, G., Weigert, A., ... & Scholich, K. (2024). Meloxicam treatment disrupts the regional structure of innate inflammation sites by targeting the pro‐inflammatory effects of prostanoids. British Journal of Pharmacology, 181(7), 1051-1067.
[13]. Banerjee, R., Chakraborty, H., & Sarkar, M. (2003). Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 59(6), 1213-1222.
[14]. Van Antwerpen, P., & Nève, J. (2004). In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. European journal of pharmacology, 496(1-3), 55-61.
[15]. Montejo, C., Barcia, E., Negro, S., & Fernández-Carballido, A. (2010). Effective antiproliferative effect of meloxicam on prostate cancer cells: development of a new controlled release system. International journal of pharmaceutics, 387(1-2), 223-229.
[16]. Türck, D., Roth, W., & Busch, U. (1996). A review of the clinical pharmacokinetics of meloxicam. Rheumatology, 35(suppl_1), 13-16.
[17]. Kreuder, A. J., Coetzee, J. F., Wulf, L. W., Schleining, J. A., KuKanich, B., Layman, L. L., & Plummer, P. J. (2012). Bioavailability and pharmacokinetics of oral meloxicam in llamas. BMC veterinary research, 8, 1-11.
[18]. Adawaren, E. O., Mukandiwa, L., Chipangura, J., Wolter, K., & Naidoo, V. (2019). Percentage of faecal excretion of meloxicam in the Cape vultures (Gyps corprotheres). Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 215, 41-46.
[19]. Nixon, E., Mays, T. P., Routh, P. A., Yeatts, J. L., Fajt, V. R., Hairgrove, T., & Baynes, R. E. (2020). Plasma, urine and tissue concentrations of Flunixin and Meloxicam in Pigs. BMC veterinary research, 16, 1-10.
[20]. Turaga, S. (2022). Development and Evaluation of a Meloxicam Extended Release Injectable Suspension (Master's thesis, University of Pittsburgh).
[21]. Malvade, P. V., Dhamak, K. V., Muntode, P. J., & Mule, P. S. (2023). Development And Evaluation Of A Meloxicam Topical Ointment For Localized Drug Delivery.
[22]. Del Favero, A. (2008). Anti-inflammatory and antipyretic analgesics and drugs used in gout. In Side Effects of Drugs Annual (Vol. 30, pp. 125-136). Elsevier.
[23]. Chikanbanjar, N., Semwal, N., & Jyakhwa, U. Analytical Method Validation of Meloxicam and Paracetamol Tablet in Combination by HPLC Method.
[24]. Enikő, C., Croitoru, M. D., Ibolya, F., & Daniela-Lucia, M. (2014). Development of a HPLC-UV method for determination of meloxicam in human plasma and pharmaceutical dosage forms. Acta Marisiensis-Seria Medica, 60(4), 142-145.
[25]. Starek, M., & Krzek, J. (2012). TLC determination of meloxicam in tablets and after acidic and alkaline hydrolysis. Acta Poloniae Pharmaceutica. Drug Research, 69(2).
[26]. Sawada, H., Korenaga, K., Kawamura, N., Mizu, H., & Yamauchi, H. (2011). A simple and easy method for determination of meloxicam in rat muscle and plasma. Chromatography, 32(3), 121-126.
[27]. Bae, J. W., Kim, M. J., Jang, C. G., & Lee, S. Y. (2007). Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. Journal of Chromatography B, 859(1), 69-73.
[28]. Nemutlu, E., & Kır, S. (2004). Validated determination of meloxicam in tablets by using UV spectrophotometry. Hacettepe University Journal of The Faculty of Pharmacy, (1), 13-24.
[29]. Cox, S., Bailey, J., White, M., Gordon, K., & Souza, M. (2017). Determination of meloxicam in egg whites and yolks using reverse phase chromatography. Journal of chromatographic science, 55(6), 610-616.
[30]. Nikolaychuk, P. A. (2023). UV-spectrophotometric determination of the active pharmaceutical ingredients meloxicam and nimesulide in cleaning validation samples with sodium carbonate. J, 6(2), 248-266.
[31]. Bandarkar, F. S., & Vavia, P. R. (2009). A stability indicating HPLC method for the determination of meloxicam in bulk and commercial formulations. Tropical Journal of Pharmaceutical Research, 8(3).
[32]. Oliveira, G. M., Dionísio, T. J., Siqueira-Sandrin, V. S., Ferrari, L. A. D. L., Colombini-Ishikiriama, B. L., Faria, F. A. C., ... & Calvo, A. M. (2023). Liquid Chromatography-Tandem Mass Spectrometry Method for Detection and Quantification of Meloxicam and 5′-Carboxymeloxicam in Oral Fluid Samples. Metabolites, 13(6), 755.
[33]. Kasem, M. A., Megahed, H. E., Moustafa, M. E., & Ibrahim, H. A. (2014). Sensitive, Direct and Rapid Spectrophotometric Method for the Determination of Meloxicam through Ion-Associate Complex Formation. J. Basic Environ. Sci, 1, 92-101.
[34]. Chaudhary, K. B., Bhardwaj, K., Verma, G., & Kumar, P. (2018). Validated Analytical Method development for the determination of Meloxicam by UV Spectroscopy in API and Pharmaceutical dosage form. Asian J. Pharm. Educ. Res, 7, 60-69.
[35]. Chaplenko, A. A., Monogarova, O. V., & Oskolok, K. V. (2018). Spectroscopic and colorimetric determination of meloxicam, lornoxicam, tenoxicam in drugs. International Journal of Pharmaceutical & Biological Archives, 9(1), 31-35.
[36]. Wali, A. F., Masoodi, M. H., Akbar, M., & Mushtaq, A. (2013). Method development and validation of a stabilityindicating rp-hplc method for analysis of meloxicam using dad detector. Asian Journal of Pharmaceutical Research and Development, 33-39.
[37]. Mahood, A. M., & Najm, N. H. (2019, July). Spectrophotometric estamation of meloxicam using charge transfer complex. In IOP Conference Series: Materials Science and Engineering (Vol. 571, No. 1, p. 012081). IOP Publishing.
[38]. Siddareddy, K., Reddy, M. A. U., Suresh, B., & Sreeramulu, J. (2018). Development and Validation of Analytical Method for Simultaneous Estimation of Bupivacaine and Meloxicam in Human Plasma Using UPLC-MS/MS. Pharmaceutical Methods, 9(1).
[39]. Hasan, S. H., Othman, N. S., & Surchi, K. M. (2015). Development and validation of a UV-Spectrophotometric method for determination of meloxicam in bulk and in tablet formulations. International Journal of Pharma Sciences and Research, 6(7), 1040-45.
[40]. Gurupadayya, B. M., Trinath, M. N., & Shilpa, K. (2013). Spectrophotometric determination of meloxicam by sodium nitroprusside and 1, 10-phenanthroline reagents in bulk and its pharmaceutical formulation.
[41]. Abed, R. I., & Hadi, H. (2021). Determination of meloxicam using direct and indirect flow injection spectrophotometry. Current Pharmaceutical Analysis, 17(2), 254-264.
[42]. Aydoğmuş, Z., & Alim, F. (2024). DETERMINATION OF MELOXICAM IN TABLETS BY THIRD DERIVATIVE UV SPECTROPHOTOMETRIC METHOD. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, 7(1), 61-67.
[43]. Atiyah, A., Hussein, K., & Ahmed, A. M. (2024). Spectrophotometric determination of Meloxicam in Pure Form and its Pharmaceutical Formulation following azo dye formation with 4-nitroaniline. Journal of the Turkish Chemical Society Section A: Chemistry, 11(4), 1461-1472.
[44]. Garcı́a, M. S., Sánchez-Pedreño, C., Albero, M. I., & Martı́, J. (2000). Spectrophotometric methods for determining meloxicam in pharmaceuticals using batch and flow-injection procedures. European journal of pharmaceutical sciences, 9(3), 311-316.
[45]. Ramesh, S., Rupali, J., Deepali, K., & Varsha, S. (2010). Development and validation of spectrophotometric methods for simultaneous estimation of paracetamol and meloxicam in pure and tablet dosage form. Der Pharm Lett, 2(2), 471-478.
[46]. Al-Momani, I. F. (2006). Indirect flow-injection spectrophotometric determination of meloxicam, tenoxicam and piroxicam in pharmaceutical formulations. Analytical sciences, 22(12), 1611-1614.
[47]. Miloğlu, F. D. Square Wave and Differential Pulse Voltammetric Determination of Meloxicam in Pharmaceutical Formulations. International Journal of PharmATA, 2(1), 1-10.
[48]. Šelešovská, R., Hlobeňová, F., Skopalová, J., Cankař, P., Janíková, L., & Chýlková, J. (2020). Electrochemical oxidation of anti-inflammatory drug meloxicam and its determination using boron doped diamond electrode. Journal of Electroanalytical Chemistry, 858, 113758.
[49]. Altınöz, S., Nemutlu, E., & Kır, S. (2002). Polarographic behaviour of meloxicam and its determination in tablet preparations and spiked plasma. Il Farmaco, 57(6), 463-468.
[50]. Rusu, A. U. R. A., Antonoaea, P. A. U. L. A., Ciurba, A., Birsan, M. A. G. D. A. L. E. N. A., Hancu, G., & Todoran, N. I. C. O. L. E. T. A. (2019). Development of a rapid capillary zone electrophoresis method to quantify levofloxacin and meloxicam from transdermal therapeutic systems. Studia Universitatis Babes-Bolyai Chemia, 64(10.24193).
[51]. Nemutlu, E., & Kir, S. (2003). Method development and validation for the analysis of meloxicam in tablets by CZE. Journal of pharmaceutical and biomedical analysis, 31(2), 393-400.
[52]. Dhandapani, B., Eswara, M. S., Susrutha, N., Rama, S., Rani, S., Sarath, T., & Celestin, R. (2010). Spectrophotometric estimation of meloxicam in bulk and its pharmaceutical formulations. International Journal of Pharma Sciences and Research (IJPSR), 1, 217-221.
[53]. Zaman, M., Hanif, M., Khan, N. U. H., Mahmood, A., Qaisar, M. N., & Ali, H. (2019). Development and validation of stability-indicating RP-HPLC method for the simultaneous determination of Tizanidine HCl and meloxicam in Rabbit's plasma. Acta Chromatographica, 31(3), 173-178.
[54]. Rani, J. D. B., & Deepti, C. A. (2023). stability indicating method development of rp-uplc, validation of simultaneous quantitation of bupivacaine and meloxicam in pure and formulation. Rasayan Journal of Chemistry, 16(3).
[55]. Karpicarov, D., Apostolova, P., Arev, M., Arsova-Sarafinovska, Z., & Gjorgjeska, B. (2023). Development and validation of HPLC method for content determination of Meloxicam in injections. KNOWLEDGE-International Journal, 57(4), 517-522.
[56]. Çelik, R. S., Bayrak, B., & Kadıoğlu, Y. (2023). Development and Validation of HPLC-UV Method for Determination of Meloxicam in Tablet Dosage Formulation. Pharmata, 3(3), 59-63.
[57]. POJARANİ, L. B., & ZARİFİAZAR, S. (2020). Formulation and chracterization of meloxicam loaded niosome-based hydrogel formulations for topical applications. EMU Journal of Pharmaceutical Sciences, 3(3), 194-204.
[58]. Ianiski, F. R., Laporta, L. V., Rubim, A. M., & Luchese, C. (2015). Validation of high performance liquid chromatography method for determination of meloxicam loaded PEGylated nanocapsules. Brazilian Journal of Pharmaceutical Sciences, 51, 823-832.